Malta - Engels - Malta Medicines Authority

mimer medical ab svärdvägen 3b, se-182 33 danderyd, sweden - nicotine - oromucosal spray - nicotine 1 mg - other nervous system drugs

Australië - Engels - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - nabiximols, quantity: 80 mg/ml - spray, solution - excipient ingredients: propylene glycol; peppermint oil; ethanol absolute - sativex is indicated as treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - ciclesonide, quantity: 50 microgram/actuation - spray, nasal - excipient ingredients: potassium sorbate; hypromellose; purified water; microcrystalline cellulose; disodium edetate; carmellose sodium; hydrochloric acid; nitrogen - omnaris nasal spray is indicated for: the treatment of seasonal allergic rhinitis in adults and children 6 years of age and older; and for the treatment of perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - nicotine - oromucosal spray, solution - 1 milligram(s) - drugs used in nicotine dependence; nicotine

Malta - Engels - Malta Medicines Authority

johnson & johnson (ireland) limited airton road tallaght, dublin 24, dublin, ireland - nicotine - oromucosal spray - nicotine 1 µg/dose - other nervous system drugs

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nafarelin, quantity: 2 mg/ml - spray, solution - excipient ingredients: benzalkonium chloride; sorbitol; glacial acetic acid; hydrochloric acid; purified water; sodium hydroxide - indications as at 31 august 1995. synarel is indicated for the hormonal management of visually proven endometriosis, including pain relief and reduction of endometriotic lesions and for use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 50 microgram/actuation - spray, suspension - excipient ingredients: benzalkonium chloride; citric acid monohydrate; sodium citrate dihydrate; dispersible cellulose; glycerol; citric acid; polysorbate 80; purified water - uniclar aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years. uniclar aqueous nasal spray 0.05% is also indicated for the treatment of nasal polyps in adult patients 18 years of age and older. uniclar aqueous nasal spray 0.05% is indicated for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without signs or symptoms of severe bacterial infection.

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - fluticasone propionate - spray - 50microgram/1dose

Ierland - Engels - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - amylmetacresol; 2,4-dichlorobenzyl alcohol; lidocaine - oromucosal spray - 0.29 mg/ 0.58 mg/0.78 milligram(s) - antiseptics; dichlorobenzyl alcohol

Australië - Engels - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg/ml (equivalent: desmopressin, qty 0.089 mg/ml) - spray, solution - excipient ingredients: dibasic sodium phosphate dihydrate; citric acid monohydrate; sodium chloride; purified water; benzalkonium chloride - diabetes insipidus:the treatment of adh-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.,nocturnal enuresis: minirin nasal spray is indicated for the symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. minirin nasal spray should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible.,renal concentrating capacity: by intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity.